Bristol Myers BMY recently secured a meaningful label expansion for Sotyktu, with the FDA approving the drug for adults with ...

President Donald Trump is pushing ahead with announcements to TrumpRx.gov as Americans look for ways to cut the costs associated with prescription drugs.

Jayant Mishra said he was approved for a copay card covering $9,450 a year. He didn't realize how fast the money would run out.

Johnson & Johnson's much-anticipated oral IL-23 inhibitor, icotrokinra, has claimed FDA approval as a first-line treatment for plaque psoriasis.

New research suggests GLP-1 drugs may increase the risk of bone and tendon injuries and other conditions, including ...

Amgen Inc. and GSK plc are reportedly set to announce their partnership with TrumpRx.gov. This collaboration is set to offer substantial discounts on prescription drugs. This move will augment the ...

President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those paid ...

GLP-1 receptor agonists like semaglutide are being used off-label by healthy people hoping to slow ageing, despite limited evidence and unknown long-term risks.

Johnson & Johnson JNJ rapidly advanced its pipeline in 2025, attaining significant clinical and regulatory milestones that will help drive growth through the back half of the decade. In 2025, it ...

Jan 27 (Reuters) - The U.S. government on Tuesday named the 15 new drugs targeted for Medicare price negotiations for 2028, including Gilead Sciences' HIV drug Biktarvy and Pfizer's arthritis ...

Diamond Hill Capital, an investment management company, released its “Mid Strategy” fourth-quarter 2025 investor letter. A ...

New guidelines recommend considering cholesterol-lowering statins in the 30s, screening all adults for hidden risk factors ...